๐ŸŽ Black Friday: 50% off Unlimited and 30% off Pro annual plans
Taysha Gene Therapies, Inc. (TSHA)
NASDAQ: TSHA ยท Real-Time Price ยท USD
3.720
-0.050 (-1.33%)
At close: Nov 20, 2026, 4:00 PM EST
3.710
-0.010 (-0.27%)
After-hours: Nov 20, 2026, 7:56 PM EST

Taysha Gene Therapies Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
5.499.778.3315.452.5-
Revenue Growth
-13.07%17.28%-46.07%517.55%--
Gross Profit
5.499.778.3315.452.5-
Operating Income
-164.44-110.5-86.62-71.37-126.03-173.27
Net Income
-156.03-109-89.3-111.57-166.01-174.52
Earnings Per Share
-0.42-0.34-0.36-0.96-3.78-4.64
EPS Growth
------

Cash & Debt

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
422.83319.77139.04143.9487.88149.1
Total Debt
54.5970.1463.1861.1159.9363.09
Net Cash (Debt)
368.24249.6275.8682.8327.9586.01
Net Cash Growth
61.32%229.08%-8.42%196.34%-67.50%-65.77%
Net Cash Per Share
0.980.780.300.710.642.28

Cash Flow & CapEx

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-140.94-93.09-81.23-73.02-88.39-117.04
Capital Expenditures
-0.72-0.74-0.37-3.87-20.62-15.3
Free Cash Flow
-141.66-93.83-81.6-76.89-109.01-132.35
Free Cash Flow Growth
------

Margins

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
100.00%100.00%100.00%100.00%100.00%-
Operating Margin
-2997.99%-1130.65%-1039.49%-461.94%-5037.05%-
Pretax Margin
-2844.63%-1115.27%-1071.62%-722.06%-6635.25%-
Profit Margin
-2844.63%-1115.27%-1071.62%-722.06%-6635.25%-
FCF Margin
-2582.59%-960.07%-979.23%-497.62%-4356.88%-

Valuation

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingNov '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PS Ratio
221.13154.1642.5521.4256.40-